<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717076</url>
  </required_header>
  <id_info>
    <org_study_id>H11_21</org_study_id>
    <nct_id>NCT04717076</nct_id>
  </id_info>
  <brief_title>PrevA Study - Evaluation of an App-based Nutritional Concept</brief_title>
  <acronym>PrevA</acronym>
  <official_title>PrevA Study - Evaluation of an App-based Nutritional Concept to Lower Cardiovascular Risk Factors (Focus: Weight Reduction)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PrevA study is designed to evaluate our developed nutritional concept to implement a&#xD;
      heart healthy diet. The nutritional concept based on nutrient-optimized daily menu plans for&#xD;
      each study day. The plans are personalized according to participants age, gender, and level&#xD;
      of physical activity. The PrevA study consists of four periods differing in the energy intake&#xD;
      specified by the menu plans.&#xD;
&#xD;
      The study is carried out in a 4-armed parallel design. In group 1, the participants receive&#xD;
      the individualized daily plans via the app coupled with the smartwatch to record participants&#xD;
      physical activity and heart rate. Groups 2 and 3 receive a printed version of the daily plans&#xD;
      with or without personal nutritional advice. The fourth group serves as a control group,&#xD;
      which receives general nutritional recommendations but no daily menu plans. During this time,&#xD;
      blood samples and urine are collected every four weeks to analyze the study parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smartphone-based communication technologies are developing rapidly, and the number of&#xD;
      so-called mobile health applications is rising. The number of validated and scientifically&#xD;
      tested offers is comparatively small. To address this weak point, we developed a personalized&#xD;
      nutritional concept to implement a heart-healthy diet. In cooperation with the Preventicus&#xD;
      GmbH, Jena, the concept was integrated in an App-based tool. In addition, the app relates to&#xD;
      a smartwatch to encourage and track physical activity. The PrevA study will be conducted to&#xD;
      evaluate the overall concept.&#xD;
&#xD;
      The nutritional concept based on nutrient-optimized daily menu plans for each study day. The&#xD;
      plans are personalized according to participants age, gender, and level of physical activity.&#xD;
&#xD;
      The study is carried out in a 4-armed parallel design. In group 1, the participants receive&#xD;
      the individualized daily plans via the app coupled with the smartwatch to record participants&#xD;
      physical activity and heart rate. Groups 2 and 3 receive a printed version of the daily plans&#xD;
      with or without personal nutritional advice. The fourth group serves as a control group,&#xD;
      which receives general nutritional recommendations but no daily menu plans.&#xD;
&#xD;
      In groups 1 to 3, the daily plans are issued in 4 energy levels. At the beginning, the test&#xD;
      subjects receive daily plans according to the recommendations for energy intake of the German&#xD;
      Nutrition Society (DGE), adapted to their age, gender, and activity level (level 1). After&#xD;
      four study weeks, the energy content of the plans is reduced to 85% of the energy intake&#xD;
      recommended by the DGE (level 2) and after further four weeks of the PrevA study the energy&#xD;
      level is reduced to 70% of the energy intake recommended by the DGE (level 3). Level 4 serves&#xD;
      as a stabilization phase and provides the energy content of level 1. The study period extends&#xD;
      over a total of 16 study weeks. During this time, blood samples and urine are collected every&#xD;
      four weeks to analyze the study parameters. In addition, anthropometric data, data on&#xD;
      personal health status and cardiovascular risk profile are assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 12, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Body weight (kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Body fat (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>systolic pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>diastolic blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal metabolic rate</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Basal metabolic rate (kcal per day) - measurement: indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Total cholesterol (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>LDL cholesterol (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>HDL cholesterol (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triacylglycerides (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Triacylglycerides (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose (fasting) (serum)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Glucose (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin (fasting) (serum)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Insulin (mU/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c (serum)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>HbA1c (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alpha prothrombin time (serum)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>alpha prothrombin time (s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (serum)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Fibrinogen (g/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High sensitive c-reactive protein (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>High sensitive c-reactive protein (mg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homocysteine (serum)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Homocysteine (Âµmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triiodothyronine (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Triiodothyronine fT3 (pmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroxine (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Thyroxine fT4 (pmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid-stimulating hormone (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Thyroid-stimulating hormone (mU/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Parathyroid hormone (ng/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Alkaline phosphatase (Âµg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Osteocalcin (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Uric acid (Âµmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Alanine aminotransferase (Âµmol/l*s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Aspartate transaminase (Âµmol/l*s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholinesterase (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Cholinesterase (Âµmol/l*s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyltransferase (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Gamma-glutamyltransferase (Âµmol/l*s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Lactate dehydrogenase (Âµmol/l*s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid distribution in plasma lipids (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Fatty acid distribution in plasma lipids (% fatty acid methyl esters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid distribution in erythrocyte lipids (erythrocytes)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Fatty acid distribution in erythrocyte lipids (% fatty acid methyl esters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin A (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin A (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin D (nmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin E (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin E (Âµmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B1 (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin B1 (nmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B2 (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin B2 (nmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B6 (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin B6 (nmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B12 (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin B12 (pmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holo-transcobalamin (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Holo-transcobalamin (pmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Folic acid (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Folic acid (Âµg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin H (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin H (ng/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin C (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Vitamin C (mg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Calcium (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium (plasma)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Potassium (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Iron (Âµmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Ferritin (Âµg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin (plasma)</measure>
    <time_frame>change from baseline after 4, 8, 12, 16 weeks</time_frame>
    <description>Transferrin (g/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iodine (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Iodine (Âµmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selenium (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Selenium (Âµmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zinc (serum)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Zinc (Âµmol/l)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Creatinine (24 h urine)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Creatinine (mmol/l)</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumine (24 h urine)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Albumine (mg/l)</description>
  </other_outcome>
  <other_outcome>
    <measure>Selenium (24 h urine)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Selenium (Âµmol/24 h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Zinc (24 h urine)</measure>
    <time_frame>change from baseline after 16 weeks</time_frame>
    <description>Zinc (Âµmol/24 h)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Reduction of Cardiovascular Risk Factors</condition>
  <arm_group>
    <arm_group_label>App-based nutritional concept and fitness tracking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>App-based nutritional concept and fitness tracking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutritional concept with individual nutritional counselling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional concept with individual nutritional counselling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutritional concept without individual nutritional counselling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional concept without individual nutritional counselling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group - no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>App-based nutritional concept and fitness tracking</intervention_name>
    <description>The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.</description>
    <arm_group_label>App-based nutritional concept and fitness tracking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutritional concept with individual nutritional counselling</intervention_name>
    <description>Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)</description>
    <arm_group_label>Nutritional concept with individual nutritional counselling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nutritional concept without individual nutritional counselling</intervention_name>
    <description>Nutritional concept based on personalized menu plans</description>
    <arm_group_label>Nutritional concept without individual nutritional counselling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary participation with documented informed consent&#xD;
&#xD;
          -  Willingness and ability to adhere to the study protocol&#xD;
&#xD;
          -  Males / female) aged â¥ 20 years and â¤ 51 years&#xD;
&#xD;
          -  BMI: â¥ 25 â¤ 35 kg / m2 (obesity grade 1)&#xD;
&#xD;
          -  Owning a smartphone (android)&#xD;
&#xD;
          -  no or moderate alcohol consumption (â¤ 2 glasses / week)&#xD;
&#xD;
          -  non-smoker (if possible)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Comorbidities:&#xD;
&#xD;
          -  Hypercholesterolemia (genetic defect / familial predisposition)&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2&#xD;
&#xD;
          -  Thyroid dysfunction (hyper- or hypothyroidism)&#xD;
&#xD;
          -  Food intolerance / allergies to ingredients in the study foods&#xD;
&#xD;
          -  Medications: lipid-lowering drugs, glucocorticoids&#xD;
&#xD;
          -  Dietary supplements: especially n-3 fatty acids, vitamin E.&#xD;
&#xD;
          -  Extremely high physical activity (daily)&#xD;
&#xD;
          -  Alcohol abuse (daily)&#xD;
&#xD;
          -  (smoker) [if there are not enough test persons available, &gt; 7 smokers should be&#xD;
             included so that a statistical analysis is possible]&#xD;
&#xD;
          -  Uncontrolled organic diseases&#xD;
&#xD;
          -  Alcohol, drug or drug abuse&#xD;
&#xD;
          -  Participation in other clinical observational studies during or 4 weeks. before&#xD;
             starting this study&#xD;
&#xD;
          -  Serious behavioral problems, emotional problems or psychiatric problems which the&#xD;
             investigator believes would lead to a lack of compliance&#xD;
&#xD;
          -  Pregnancy, breastfeeding and unsafe contraception&#xD;
&#xD;
          -  Other reasons that are considered important by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Dawczynski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Schiller-University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Dawczynski, PhD</last_name>
    <phone>+49 3641 949656</phone>
    <email>christine.dawczynski@uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maren Biernath, M.Sc.</last_name>
    <phone>+49 3641 949656</phone>
    <email>maren.biernath@uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Friedrich-Schiller University</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Dawczynski, PhD</last_name>
      <phone>+3641 949656</phone>
      <email>christine.dawczynski@uni-jena.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Christine Dawczynski,PhD</investigator_full_name>
    <investigator_title>PhD, Head of Junior Research Group Nutritional Concepts, University of Jena</investigator_title>
  </responsible_party>
  <keyword>personalized nutritional concept, weight reduction, mHealth</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

